Success Story: Advancing Multi-Omics Research for Atherosclerosis and Liver Cancer: NIW Approval Secured for a Biomedical Science Researcher from Russia
Client’s Testimonial:
“I’m deeply grateful that we received the approval notice for my I-140 petition. Thank you so much for all your hard work and support throughout this process!”
On October 7th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Research Associate III in the field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Research Associate III
Country of Origin: Russia
State of Residence at the Time of Filing: California
Approval Notice Date: October 7th, 2026
Processing Time: 2 years, 2 months, 12 days (Premium Processing Requested)
Case Summary:
We are pleased to share the NIW approval of a biomedical science researcher whose proposed endeavor focuses on integrating immune cell composition data with other omics data to better understand disease mechanisms and support the development of treatments for atherosclerosis and liver cancer. The client’s research combines immunology with transcriptomic, proteomic, and metabolomic approaches to investigate interactions between immune cells and disease processes, with the broader goal of improving patient outcomes and advancing personalized medicine. At the time of filing, the client was employed as a Research Associate III at a U.S. medical center, where she conducted biomedical research involving molecular and cellular biology methods and immunological studies of liver cancer and atherosclerosis.
Research with National Importance
The client’s proposed research addresses important public health challenges associated with atherosclerosis and liver cancer by using multi-omics approaches to clarify complex molecular and immune interactions. Integrating different types of biological data can improve understanding of disease mechanisms and help researchers identify more targeted treatment strategies. The petition connected this work to improved cancer classification, treatment development, personalized medicine, and better patient outcomes in the United States. It also documented support for the client’s research from major U.S. biomedical research agencies, further reflecting the relevance of her work to public health priorities.
Academic Contributions and Recognition
At the time of filing, the client had documented her research in 10 peer-reviewed journal articles, including first- and co-first-authored work, as well as 8 abstracts and 1 patent. Her publications had received 96 citations, and she had completed 1 peer review for a scholarly journal. These accomplishments reflected her developing expertise across immunology, cancer research, atherosclerosis, and drug discovery.
The petition further demonstrated the significance of the client’s work through citation impact and independent use of her findings. Three of her papers ranked among the top 10% most-cited Clinical Medicine articles for their respective years, while another ranked among the top 20%. Independent researchers had relied on her work involving anticancer compounds, liver cancer signaling pathways, and genetic testing methods to inform subsequent studies and treatment-focused research. This evidence, together with her publication record and documented research support, was presented as showing that she was well positioned to continue advancing her proposed endeavor.
Recognition from Experts
Experts in the field also recognized the practical significance of the client’s prior work in cancer genetics and diagnostic research.
One expert noted:
“[Client]'s research critically addresses the growing demand for cost-effective genetic testing and faster analysis turnaround times for breast cancer. Her work thus contributes to more efficient and accessible breast cancer diagnostics.”
This assessment further illustrates how the client’s earlier work in genetic testing supported more efficient diagnostic approaches and contributed to her broader record of research aimed at improving cancer-related care.
NIW Approval and Outlook
The petition sought EB-2 NIW classification based on the client’s advanced degree and presented her education, biomedical research experience, publication and citation record, peer-review activity, independent research influence, and continued work in immunology to establish that she satisfied the Matter of Dhanasar framework.
The I-140 NIW petition was filed on July 25th, 2024, later upgraded to Premium Processing, and approved on October 7th, 2026. This outcome supports the client’s continued efforts to advance multi-omics and immunological research that may improve understanding of complex diseases and contribute to more targeted treatment strategies.